The present study also provided preliminary evidence of the anti-tumour activity of BGB-A333 in combination with tislelizumab in PD-1/PD-L1 inhibitor naïve patients with advanced solid tumours, most of whom had received at least one prior line of systemic therapy. Here, PDCD1 is linked to neoplasm.